Corrigendum: Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKT inhibitor MK2206 in mammary cancer models (Oncology Reports (2018) 40 (1545-1553) DOI: 10.3892/or.2018.6313)

Ronald A. Lubet, Vernon E. Steele, M. M. Juliana, Ann Bode, Fariba Moeinpour, Clinton J. Grubbs

Research output: Contribution to journalComment/debatepeer-review

Abstract

The AKT inhibitor employed in this article was identified as MK 2206 (8-[4-(1-aminocyclobutyl) phenyl]-9-phenyl-1,2,4-triazolo[3,4-f][1,6]naphthyridin-3(2H)-one hydrochloride (1:2). However, another AKT inhibitor was actually used, which is typically identified as Akt I-1,2 (HC,I. IPA (2-[4-(3-phenylquinoxalin-2-yl)phenyl]propan-2-amine hydrochloride isopropanol (1:1:1). Therefore, all references to MK 2206 in the paper should have been made to Akt I-1.2. Based on the experience of the present authors with a range of targeted inhibitors, it is expected that both inhibitors would have given rise to similar results; therefore, the results obtained in the paper are not likely to have been greatly affected as a consequence of the use of the alternative inhibitor. The authors regret that this error was not identified sooner, prior to the publication of the article, and regret any inconvenience that has been caused.

Original languageEnglish (US)
Number of pages1
JournalOncology Reports
Volume41
Issue number1
DOIs
StatePublished - Jan 2019

PubMed: MeSH publication types

  • Journal Article
  • Published Erratum

Fingerprint Dive into the research topics of 'Corrigendum: Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKT inhibitor MK2206 in mammary cancer models (Oncology Reports (2018) 40 (1545-1553) DOI: 10.3892/or.2018.6313)'. Together they form a unique fingerprint.

Cite this